Antibody Fragments Market Size, Share & Trends Analysis Report By Specificity (Monoclonal Antibodies, Polyclonal Antibodies), By Type, By Therapy, By Application, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Antibody Fragments market size is expected to hit around USD 12.36 billion by 2030 from valued at USD 8.14 billion in 2022 and growing at a CAGR of 5.80% from 2022 to 2030.

Key Takeaways:

  • By specificity, monoclonal antibodies held the largest share in 2021 as they are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies
  • Based on type, the scFv segment is anticipated to witness the fastest growth in the coming years. They provide several advantages such as multivalency, heterologous production, low molecular weight, and multimeric form over the parent mAb
  • By therapy, the monoclonal antibodies segment led the market in 2021. Ranibizumab (Lucentis) captured the largest revenue share in 2021 as these are used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), and others
  • By application, the cancer segment is expected to witness the fastest growth over the forecast period owing to the increasing prevalence of cancer globally, which is resulting in the increasing adoption of antibody fragments for therapeutic purposes
  • North America dominated the market in 2021 owing to the increasing prevalence of immunodeficiency diseases, which has led to the increasing demand for antibody fragments for research purposes
  • Asia Pacific is expected to grow considerably in the future owing to increasing private and public partnership investments in biotech and pharmaceutical research. This has fueled the adoption of antibody fragments

 Fragment antibodies are a promising tool in diagnostic and imaging as they are capable of identifying cellular proteins with high specificity and affinity. They can be easily linked to radioisotopes, fluorescent enzymes, or molecules that could tag specific biomarkers to the patients. Moreover, they have produced easier steps compared to complex antibodies, making them possibly faster to produce high yields.

The COVID-19 pandemic positively impacted market growth. For instance, in September 2020, a study published by researchers from Karolinska Institutet in Sweden suggested that antibody fragments type could neutralize SARS-CoV-2. They have also suggested that antibody fragments could be cheaply produced, making them a promising candidate to prevent COVID-19 infection. Similarly, in February 2022, a research article stated that human inhalable antibody fragments have potential application to neutralize SARS-CoV-2 variants for COVID-19 therapy.

Furthermore, the utilization of antibody-based therapeutics has shown to be a promising tool for clinical purposes in patients with cancer. For instance, multiple instances have shown the effectiveness of antibody-drug conjugates in the treatment of lymphomas and solid tumors. However, one of the key factors limiting the effectiveness of antibody-targeted cancer therapies could be the partial penetration of the antibody-drug conjugate in the tumor. The introduction of advanced recombinant DNA technology has revolutionized pharmaceuticals for diagnosis and therapeutics. The minimal antigen-binding fragments, including single variable domain (sVD), fragment antigen binding (Fab), and Fragment variable (Fv), have emerged as a probable alternative to monoclonal antibodies in several applications. These factors would further drive the market in the coming years.

Report Scope of the Antibody Fragments Market

Report Coverage

Details

Market Size

USD 12.36 Billion by 2030

Growth Rate

CAGR of 5.80% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

Specificity, type, therapy, application nd Region,

Companies Mentioned

Pfizer Inc.; Ablynx; Novartis AG; Genentech, Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Johnson & Johnson Private Limited; Lilly

 

Specificity Insights

The monoclonal antibodies segment captured the largest revenue share of over 96.8% in 2021. Monoclonal antibodies (mAbs) are considered a significant class of therapeutic agents recommended in the therapy of several forms of malignancies. However, the applications of conventional mAbs may also encounter various limitations in anticancer immunotherapies such as adverse effects and insufficient efficacy. The application of antibody fragments for cancer therapy has gained wider recognition than any other therapeutic application.

However, its application to develop pharmacological tools for the treatment of autoimmune diseases and infectious diseases has been increasing expeditiously. For instance, in March 2019, researchers from the University of Utah Health started their research on disabling the specific immune cell sets that cause stress in inflammatory diseases, while maintaining the integrity of healthy immune cells to allow them to carry out their tasks.

Polyclonal antibodies (pAbs) have high specificity and flexibility and are much better than monoclonal antibodies for clinical applications. pAbs are secreted by different B-cell clones, therefore its heterogenous nature allows them to bind with several epitopes of an antigen. As the antibodies are mostly used as reagents, most of the manufacturers produce pAbs. However, since pAbs antibody reagents are inconsistent in nature, researchers have had difficulty using them since it interferes with their research studies. These are some of the factors that might limit the use of polyclonal antibodies, hence hindering the expansion of the market as a whole.

Type Insights

The FAB segment captured the largest revenue share of over 86.0% in 2021 as it is the first generation of antibody fragments. The increasing prevalence of cancer, infectious diseases, and autoimmune diseases has created a high demand for F(ab) fragments, thus fueling segment growth. Also, the approval and launch of novel therapies to facilitate the treatment of life-threatening diseases are expected to support segment growth. However, the market share is anticipated to decline over time with the introduction of the second and third-generation molecules of antibody fragments since the quality of molecules is increasing.

Single chain variable fragments (scFvs) are anticipated to register the fastest growth rate over the forecast period. They provide several advantages such as heterologous production, multivalency, low molecular weight, and multimeric form over the mAb. It is used for various medical applications, including bioimaging and targeted therapy. The scFv phage display antibody technology has become one of the most popular methods for developing recombinant antibodies. These factors are contributing to segment growth.

Therapy Insights

The monoclonal antibodies segment led the market and held a revenue share of over 96.0% in 2021. The Ranibizumab (Lucentis) segment captured the largest revenue share in 2021. Ranibizumab is a monoclonal antibody fragment that is produced in E.coli cells by recombinant DNA technology. In the pharmaceutical sector, it is present in the form of injection wherein it is used for the treatment of visual impairment due to diabetic macular edema, neovascular (wet) age-related macular degeneration (AMD), proliferative diabetic retinopathy (PDR), and others. Several academies and companies are working to understand the challenges and seek opportunities that could influence Ranibizumab R&D.

Beovu (brolucizumab-dbll) is anticipated to witness the fastest growth over the forecast period. It is a monoclonal single-chain Fv antibody fragment used for ophthalmic intravitreal injection. Moreover, in June 2022, the FDA approved Beovu (brolucizumab-dbl) to be used for the treatment of patients suffering from diabetic macular edema (DME). Advancements in this segment are anticipated to drive the market in the coming years.

Application Insights

The immunodeficiency segment held the largest revenue share of over 86.0% in 2021 owing to the increasing prevalence of the disease globally. According to the National Organization for Rare Disorders (NORD), this disease affects around 200,000 Americans. Furthermore, increasing partnerships and collaborations for the development of novel therapies for immunocompromised patients are anticipated to support segment growth. For instance, in January 2020, Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, entered into a partnership agreement with Astellas Pharma Inc., a Japanese pharmaceutical company, to develop and commercialize TCR T cell therapies and stem-cell-derived allogeneic chimeric antigen receptor (CAR)-T to treat a huge patient population suffering from immunodeficiency induced from several forms of cancers, including solid tumors.

The cancer segment is expected to witness the fastest growth during the forecast period. The high prevalence of cancer globally is one of the major factors contributing to the growth of the market over the forecast period. The American Cancer Society estimated that in 2022, around 1.9 million new cases of cancer are to be reported in the U.S., and around 609,360 deaths are to be witnessed due to cancer. According to a report published by the International Agency for Research on Cancer, around 1 in 6 women and 1 in 5 men can develop cancer during their lifetime. Thus, such a high incidence of cancer is anticipated to boost the adoption of novel and efficient cancer diagnostic and therapeutic methods.

The others segment including chronic diseases such as age-related macular degeneration (AMD) and infectious diseases such as HIV/AIDS and influenza is anticipated to witness significant growth in the coming years. Moreover, key market players are engaged in developing antibody fragments for eye disorders that are in preclinical and clinical development stages. For instance, Lampalizumab, a Fab developed by Roche for geographic atrophy, is an advanced form of age-related macular degeneration (AMD).

Regional Insights

North America dominated the market in 2021 with a revenue share of over 51.0% owing to the expansion of the regional pharmaceutical industries leading to the rising demand for antibody fragments. Moreover, the increasing prevalence of immunodeficiency diseases and cancer has led to the increasing demand for antibody fragments for research purposes.

Asia Pacific is anticipated to witness significant growth over the forecast period owing to the developing medical tourism market. India and China are anticipated to dominate the market owing to the growing focus on the biologics manufacturing sector. For instance, in May 2020, The Centre for Cellular and Molecular Biology and the University of Hyderabad entered into a collaboration with Vins Bioproducts Ltd. to develop immunotherapy based on antibody fragments that provide immediate treatment for COVID-19.

Some of the prominent players in the Antibody Fragments Market include:

  • Pfizer Inc.
  • Albynx
  • Novartis AG
  • Genentech, Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Private Limited
  • Lilly

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antibody Fragments market

  • Specificity
    • Monoclonal Antibodies
    • Polyclonal Antibodies
  • Type
    • FAB
    • scFv
    • sdAb
    • Others
  • Therapy
    • Monoclonal Antibodies
      • Praxbind (idarucizumab)
      • Ranibizumab (Lucentis)
      • Certolizumab pegol (Cimzia)
      • Iodine (1311) Metuximab/ Licartin
      • Beovu (brolucizumab-dbll)
      • Cablivi (caplacizumab-yhdp)
      • Blinatumomab/
    • PAB
      • CroFab
      • Anavip
      • Anascorp
      • Botulism Antitoxin Heptavalent (HBAT)
      • Digibind
      • DigiFab
    • Pipeline
      • AFM13
      • HPN-424
      • MGD007
      • Tebotelimab (MGD013)
      • Bentracimab (PB2452)
      • Flotetuzumab (MGD006)
      • AK104
      • Ozoralizumab
      • Sonelokimab (ALX0761)
  • Application
    • Cancer
    • Immunodeficiency
    • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Antibody Fragments industry analysis from 2022 to 2030 to identify the prevailing Antibody Fragments industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Antibody Fragments industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Antibody Fragments industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7535
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000